Australia's most trusted
source of pharma news
Posted 26 March 2024 PM
Aussie biotech Clarity Pharmaceuticals today launched a $121 million fully underwritten equity raising to advance its portfolio of radiopharmaceuticals, as it charges towards significant milestones for its therapeutic and diagnostic product pipeline.
The Sydney-based company achieved spectacular results late last year in its Phase 1/2a SECuRE trial which saw the first patient with metastatic castrate-resistant prostate cancer administered a second dose of 67Cu-SAR-bisPSMA experience a drop in cancer to undetectable levels.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.